R
Rolf W. Hartmann
Researcher at Saarland University
Publications - 371
Citations - 8686
Rolf W. Hartmann is an academic researcher from Saarland University. The author has contributed to research in topics: Aromatase & Enzyme. The author has an hindex of 47, co-authored 365 publications receiving 7834 citations. Previous affiliations of Rolf W. Hartmann include University of Regensburg & Free University of Berlin.
Papers
More filters
Journal ArticleDOI
Aldosterone Synthase Inhibitors as Promising Treatments for Mineralocorticoid Dependent Cardiovascular and Renal Diseases
TL;DR: Besides the well-known roles of aldosterone as a mineralocorticoid in regulating homeostasis of electrolytes and volume, recent studies revealed that it is also a potent proinflammation factor inducing reactive oxygen species and up-regulating a panel of fibrosis related genes.
Journal ArticleDOI
Novel Imidazol-1-ylmethyl Substituted 1,2,5,6-Tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as Potent and Selective CYP11B1 Inhibitors for the Treatment of Cushing’s Syndrome
TL;DR: Cyclopropyl analogue 4 was identified as a CYP11B1 inhibitor more potent than leads and more selective than I and metyrapone, and showed potent inhibition of rat CYP 11B1 and good selectivity over human CYP17 and CYP19.
Journal ArticleDOI
Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17)—Part II: Core rigidification and influence of substituents at the methylene bridge
Qingzhong Hu,Matthias Negri,Kerstin Jahn-Hoffmann,Yan Zhuang,Sureyya Olgen,Marc Bartels,Ursula Müller-Vieira,Thomas Lauterbach,Rolf W. Hartmann +8 more
TL;DR: Thirty-five novel substituted imidazolyl methylene biphenyls synthesized as CYP17 inhibitors for the potential treatment of prostate cancer were synthesized, with the core rigidified compounds being the most active ones, being much more potent than Ketoconazole and reaching the activity of Abiraterone.
Journal ArticleDOI
Antiestrogens. Synthesis and evaluation of mammary tumor inhibiting activity of 1,1,2,2-tetraalkyl-1,2 -diphenylethanes.
TL;DR: Compounds 23 and 26 exhibited a dose-dependent inhibition of the tumor growth, having a strong effect at a dose of 20 (mg/kg)/day (compound 23), and strongly inhibited the estrone-stimulated mouse uterine growth.
Journal ArticleDOI
Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
TL;DR: In this study, the first dual inhibitor of CYP17 and CYP11B1 (the enzyme responsible for the last step in glucocorticoid biosynthesis) is described and a series of biphenylmethylene pyridines has been designed, synthesized, and tested as CYP 17 and CYB11B 1 inhibitors.